Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890825 · ClinicalTrials.gov registry record · Phase 2
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 20
- Study locations
NCT00890825 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by AstraZeneca. The registered enrollment target is 88 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00890825, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG docetaxel
- DRUG AZD6244
Study Locations (20)
Other
- Research Site - Brussels
- Research Site - Charleroi
- Research Site - Edegem
- Research Site - Leuven
- Research Site - Liège
- Research Site - Liège
- Research Site - Belo Horizonte
- Research Site - Ijuí
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - Santo André
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Plovdiv
- Research Site - Sofia
California
- Research Site - Los Angeles
Colorado
- Research Site - Aurora
Massachusetts
- Research Site - Boston
Ohio
- Research Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-04-20 |
| Est. Completion | 2016-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890825
The ClinicalTrials.gov registry entry for NCT00890825 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00890825 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00890825 about?
NCT00890825 is a clinical study titled "AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients". The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
What is the current status of trial NCT00890825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2009-04-20. Estimated completion is 2016-11-02.
What conditions does trial NCT00890825 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00890825?
The interventions under investigation include: Placebo (DRUG), docetaxel (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00890825?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00890825 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.